We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

93 hedge funds and large institutions have $101M invested in Tvardi Therapeutics in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less call options, than puts

Call options by funds: $91K | Put options by funds: $98K

2% less funds holding

Funds holding: 95 → 93 (-2)

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

70% less capital invested

Capital invested by funds: $341M → $101M (-$240M)

Holders
93
Holders Change
-2
Holders Change %
-2.11%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
35
Reduced
29
Closed
15
Calls
$91K
Puts
$98K
Net Calls
-$7K
Net Calls Change
-$375K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$3.55M
2
RCP
Rho Capital Partners
New York
+$3.32M
3
CPM
Chesapeake Partners Management
Maryland
+$3.14M
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.36M
5
ARTA
A.R.T. Advisors
New York
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.9M
2
EAM
EverPoint Asset Management
Connecticut
-$15.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.94M
4
PCA
Private Capital Advisors
Connecticut
-$4.16M
5
SFM
Sphera Funds Management
Israel
-$3.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCP
1
Rho Capital Partners
New York
$19.1M +$3.32M +11,111 +15%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$9.9M -$18.9M -63,438 -59%
SAM
3
Sectoral Asset Management
Quebec, Canada
$7.54M – – –
CPM
4
Chesapeake Partners Management
Maryland
$6.2M +$3.14M +10,519 +61%
BFA
5
BlackRock Fund Advisors
California
$5.41M +$142K +477 +2%
OM
6
Opaleye Management
Massachusetts
$5.32M +$3.55M +11,889 +100%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.28M +$252K +845 +5%
Jennison Associates
8
Jennison Associates
New York
$4.11M +$35.2K +118 +0.6%
Franklin Resources
9
Franklin Resources
California
$3.8M – – –
JP Morgan Chase
10
JP Morgan Chase
New York
$3.19M +$1.36M +4,550 +47%
Allianz Asset Management
11
Allianz Asset Management
Germany
$2.75M -$16.7K -56 -0.5%
BIT
12
BlackRock Institutional Trust
California
$2.59M -$42.4K -142 -1%
Millennium Management
13
Millennium Management
New York
$2.43M -$3.24M -10,840 -50%
State Street
14
State Street
Massachusetts
$2.02M +$343K +1,149 +15%
DCM
15
DAFNA Capital Management
California
$1.66M +$811K +2,714 +58%
CWG
16
C WorldWide Group
Denmark
$1.63M – – –
TAM
17
Tiverton Asset Management
Delaware
$1.43M -$169K -565 -8%
Northern Trust
18
Northern Trust
Illinois
$1.43M -$13.1K -44 -0.7%
WSA
19
Wall Street Associates
California
$1.2M – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$886K – – –
SKK
21
Shepherd Kaplan Krochuk
Massachusetts
$882K +$650K +2,177 +123%
ARTA
22
A.R.T. Advisors
New York
$866K +$1.03M +3,439 +798%
AQR Capital Management
23
AQR Capital Management
Connecticut
$779K +$115K +385 +12%
TCIM
24
TIAA CREF Investment Management
New York
$640K – – –
Bank of New York Mellon
25
Bank of New York Mellon
New York
$640K +$43.9K +147 +5%
1
2 3 4 5

TVRD Hedge Fund Activity: Q1 2016 in Review

93 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2016, worth a combined $101M — down 70% from $341M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TVRD and 13 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 35 added.

The largest buyer was Opaleye Management, adding an estimated $3.55M. The largest seller was Fidelity Investments, cutting an estimated $18.9M.

  • 93 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2016, down from 95 in Q4 2015.
  • Funds reported $101M of Tvardi Therapeutics stock for Q1 2016, down 70% quarter-over-quarter.
  • 13 funds opened new Tvardi Therapeutics positions in Q1 2016 and 15 closed out, a net change of -2 holders.
  • The largest Tvardi Therapeutics buyer in Q1 2016 was Opaleye Management, an estimated $3.55M added.
  • The largest Tvardi Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $18.9M sold.

Based on aggregated 13F filings for Q1 2016.